Anbio Biotechnology (NNNN) Receivables (2023 - 2025)

Anbio Biotechnology has reported Receivables over the past 3 years, most recently at $3.7 million for Q4 2025.

  • Quarterly results put Receivables at $3.7 million for Q4 2025, up 243.44% from a year ago — trailing twelve months through Dec 2025 was $3.7 million (up 243.44% YoY), and the annual figure for FY2025 was $3.7 million, up 243.44%.
  • Receivables for Q4 2025 was $3.7 million at Anbio Biotechnology, up from $1.1 million in the prior quarter.
  • Over the last five years, Receivables for NNNN hit a ceiling of $3.7 million in Q4 2025 and a floor of $1.1 million in Q4 2024.
  • Median Receivables over the past 3 years was $1.9 million (2023), compared with a mean of $2.2 million.
  • Biggest five-year swings in Receivables: crashed 43.51% in 2024 and later surged 243.44% in 2025.
  • Anbio Biotechnology's Receivables stood at $1.9 million in 2023, then tumbled by 43.51% to $1.1 million in 2024, then surged by 243.44% to $3.7 million in 2025.
  • The last three reported values for Receivables were $3.7 million (Q4 2025), $1.1 million (Q4 2024), and $1.9 million (Q4 2023) per Business Quant data.